Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 1.6 USD -0.62% Market Closed
Market Cap: 85.9m USD

EV/EBITDA
Enterprise Value to EBITDA

-1.6
Current
0.3
Median
5.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.6
=
Enterprise Value
68.1m USD
/
EBITDA
-42.6m USD
EBITDA Growth EV/EBITDA to Growth
US
Quince Therapeutics Inc
NASDAQ:QNCX
Average EV/EBITDA: 15.4
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 804.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
14.7
12%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -465.6 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A